Breast organoid suspension cultures maintain long-term estrogen receptor expression and responsiveness

Breast organoid suspension cultures maintain long-term estrogen receptor expression and responsiveness

Introduction

Breast cancer is a heterogeneous disease classified into distinct subtypes based on pathologic status of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) combined with molecular examination of other markers1,2,3,4. Most breast cancers are ER-positive (about 70%) with or without co-expression of PR5. In contrast to normal breast, ER+ proliferating cells are common in luminal tumors and their proliferation is inhibited by ER-antagonists1,2,3,4, suggesting that the development of ER+ human breast cancer is associated with dysregulation of ER and proliferation. Investigations of the evolution of ER+ cells, the mechanisms of their transformation, and the effects of distinct genetic alterations in ER+ cells have been limited due to lack of culture conditions that maintain ER expression and estrogen responsiveness in breast epithelial cells.

The advent of organoid technology has enabled the development of normal breast organoid cultures that preserve the differentiated epithelial cell lineages of the native tissue: basal/myoepithelial (BA) cells, luminal adaptive secretory precursor (LASP) and hormone-sensing (HS) cells. These cultures have enabled the investigation of different stages of mammary gland development as well as characterization of the earliest changes in breast tissues of women at high risk of developing breast cancer6,7. However, existing organoid culture protocols, which involve embedding of cells in solid 100% reconstituted basement membrane (™Matrigel) domes, are tedious to passage, difficult to scale for high throughput studies, and generally do not robustly preserve ER expression and responsiveness over time. These limitations preclude the generation of organoid cultures from small amounts of tissue and the ability to study the evolution of ER+ tumor cells.

Here, we describe a modified normal breast organoid culture system that preserves the three breast epithelial lineages, increases organoid growth rate and uniformity, and maintains ERα expression and estrogen responsiveness in HS cells in long-term culture.

Results

Suspension culture produces larger and more uniform human breast organoids than conventional Matrigel domes

Several studies of cancer organoids have suggested that suspension cultures supplemented with a low percentage of Matrigel can not only be used as an alternative culture condition but also increase cancer organoid expansion rate compared to traditional cultures embedded in solid Matrigel domes8,9,10,11. To evaluate whether suspension culture could also shorten the expansion time of normal breast organoids, we first tested seven previously established organoid lines. These seven organoid lines were generated from normal breast tissues obtained from reduction mammoplasty or prophylactic mastectomy using conventional Matrigel dome cultures as previously described6,12,13. We then dissociated these organoids to small clusters (20–60 cells per organoid) and re-cultured half in solid Matrigel domes and the other half in ultra-low attachment plates with 5% Matrigel in the media and monitored growth and morphology of the organoids for more than two months (Fig. 1a, Supplementary Fig. 1a). As previously described, human breast organoids cultured in solid Matrigel domes are heterogeneous, forming various types of structures in the different organoid lines6,13. In contrast, organoids cultured in suspension were generally larger in size and exhibited a more uniform sphere-like structure (Fig. 1b, c, Supplementary Fig. 1b). Since we observed larger organoids in suspension cultures, we assessed the proportion of proliferating cells in ORG14 using two methods: EdU labeling and flow cytometry (see Methods) as well as Ki-67 immunofluorescence staining (Supplementary Fig. 1c, d). The ORG14 organoids in the suspension cultures contained a larger proportion of proliferating cells than organoids in Matrigel domes (Supplementary Fig. 1c–e). There was very little variation in organoid size for the dome cultures. Moreover, there was a correlation between the fraction of Ki-67+ cells and organoid size only in the suspension cultures (r = 0.57, Supplementary Fig. 1f), indicating that larger organoids contain more proliferating cells.

Fig. 1: Propagation of normal human breast organoids as suspension cultures.
Breast organoid suspension cultures maintain long-term estrogen receptor expression and responsiveness

a Established breast organoid cultures derived using the conventional Matrigel dome method (passage 5–614) were dissociated and either re-cultured in Matrigel domes or as suspension cultures in 5% Matrigel for more than two months. b Representative brightfield images of six matched organoid lines grown as Matrigel domes (MD) or suspension cultures (SC) and their corresponding percentage of HS, LASP and BA cells based on FACS sorting using EpCAM and CD49f antibodies (4× magnification, scale bar 200 μm). c Mean organoid size of the indicated matched cultures grown as domes or in suspension. A total of 30 organoids per line per culture condition were measured using Image J. **p value < 0.01, ***p value < 0.001, ****p value < 0.0001, paired t-Test, two-tailed.

Full size image

To assess the representation of breast epithelial lineages in the suspension organoid cultures, we performed flow cytometry using the canonical lineage markers EpCAM and CD49f to compare the proportion of HS (EpCAMhigh CD49flow), LASP (EpCAMhigh CD49fhigh), and BA (EpCAMlow CD49fhigh) cells to organoids cultured in solid Matrigel domes. These three major epithelial cell types were all maintained in the two culture conditions but, as previously reported14, their proportions varied in cultures from different donors. Overall, the proportions of the three cell types were roughly similar although four out of six organoid lines contained a higher HS proportion in the suspension cultures (Fig. 1b).

Next, we examined the morphology of the suspension organoids by performing immunofluorescence of established breast epithelial lineage markers: FOXA1 for HS, CD133 for LASP, and α-SMA for BA cells. In addition to validating the proportions we identified by flow cytometry, we found that all three epithelial cell types were present within most individual organoids and exhibited a uniform staining pattern, with luminal cells (HS and LASP cells) in the interior and BA cells distributed over the outer area of the organoids (Supplementary Fig. 1g), indicating that Matrigel suspension preserves the ability of normal breast epithelial cells to self-organize into acinar-like structures under these conditions. Previously, we had found that bilayered structures were lost with passage in dome cultures12,14.

Breast organoids cultured in suspension contain a higher proportion of proliferating cells than those in Matrigel domes

To evaluate the two culture methods for establishment of organoids directly from breast tissues, we thawed frozen minced breast tissues from three donors as previously described14, dissociated them and seeded the small clusters in either Matrigel domes or 5% Matrigel suspension as described above. We used TryPLE to passage the organoids and to free the cultures of debris and contaminating stromal cells. We noted differences in the morphology and size of organoids in these three cultures through the early passages. Since suspension cultures reached confluency faster than dome cultures, we diluted the suspension organoids into extra wells (after ~2 wks) until the dome cultures reached confluency (after ~4 wks) to ensure that the passage number was identical for each culture condition (Fig. 2a). After five passages with TryPLE, we imaged both Matrigel domes and suspension cultures after 10 days. The 5% Matrigel suspension cultures contained more and larger organoids than those generated in domes (Fig. 2b). We assessed the proportion of proliferating cells using EdU labeling as described above. Organoids in the suspension cultures contained a larger proportion of proliferating cells than those in Matrigel domes (Fig. 2c). We further analyzed proliferation specifically within the three epithelial cell types by flow sorting the cells using antibodies to EpCAM and CD49f (Fig. 2d and Supplementary Fig. 2a). Although the proportion of all three mammary epithelial lineages was largely comparable between the culture conditions in the three organoid lines, the fraction of proliferating cells within each lineage was higher in the suspension cultures than the Matrigel domes. We validated this finding using Ki-67 staining of ORG6 at passage 5 (Supplementary Fig. 2b). The percentage of Ki-67+ cells was consistent with what we observed with EdU labeling and confirmed that the fraction of proliferative cells was higher in suspension than Matrigel dome cultures (average of 45.9% in SC vs 38.2% in MD, Supplementary Fig. 2c). Consistent with what we observed with established organoid cultures, the percentage of Ki-67+ cells correlated with organoid size only in suspension cultures (Supplementary Fig. 2d).

Fig. 2: Breast organoid suspension cultures have a higher fraction of proliferating cells than Matrigel dome cultures.
figure 2

a Minced normal breast tissues from three reductive mammoplasty samples were dissociated and used to derive matched Matrigel dome and suspension organoid cultures. Scheme was created with BioRender.com b Representative brightfield images of the three matched organoid lines grown as Matrigel domes (MD) or suspension cultures (SC) for 5 passages and their corresponding mean organoid size. Scale bar 200 μm. A total of 30 organoids per line per culture condition was measured using Image J. ***p value < 0.001, ****p value < 0.0001, paired t-Test, two-tailed. c Percentage of EdU-positive cells in the three organoid lines at passage 5. d Percentage of HS, LASP and BA cells based on FACS analyses of EpCAM/CD49f expression. e Percentage of EdU-positive cells in the indicated organoid lines 10 days after changing the culture condition from suspension to Matrigel domes (SC - > MD) or reseeding as suspension culture (SC - > SC).

Full size image

To evaluate whether the differences in organoid proliferation are reversible, we then performed a short-term culture condition switch by transferring half of organoids from six organoid lines in suspension cultures into Matrigel domes for 10 days before Click-iT EdU assays (Fig. 2e). In all six organoid lines, there was a reduction in proliferation after transfer to Matrigel domes (average of 42% vs 22%; p-value < 0.01, paired t-Test, two tailed) (Fig. 2e). Moreover, half the organoid lines contain a higher proportion of proliferating HS cells and all organoid lines have more proliferating LASP and BA cells in suspension cultures compared to Matrigel domes (Supplementary Fig. 2e).

Organoids cultured in suspension preserve breast epithelial cell lineage fidelity

To assess the breast epithelial lineage fidelity in our organoid suspension cultures, we compared the gene expression profiles of EpCAM/CD49f-sorted HS, LASP, and BA cells from both dome and suspension organoids of ORG6 at passage 6–7 (Fig. 3a). RNA was extracted from the sorted cells and bulk sequenced (RNA-seq) to compare the gene expression patterns among the isolated cells. Principal Component Analysis (PCA) showed that the three breast lineage cell types clustered separately (Fig. 3b). We then examined the expression of breast lineage signatures defined from primary breast tissues by Gray et al.15. As shown in Fig. 3, the three breast epithelial lineages maintained their lineage fidelity in long-term organoid cultures (Fig. 3c–e). Among these three lineage cell types, HS cells preserved HS signature gene expression more faithfully than LASP and BA cells (Fig. 3c). In addition, LASP cells were found to express some HS and BA signature genes. The expression of these HS and BA genes could be due to cells undergoing differentiation from LASP to HS cells or BA cells. Previous reports indicated that luminal progenitors can generate both HS and BA like cells in vitro6,13,16.

Fig. 3: Organoid suspension cultures preserve breast epithelial lineage fidelity.
figure 3

a Organoid cultures were dissociated into single cells, FACS sorted into HS, LASP and BA cells based on differential expression of EpCAM/CD49f and total RNA was extracted for bulk RNA sequencing. b Principal Component Analysis (PCA) plot showing the HS, LASP and BA cell clusters isolated from organoids in Matrigel domes and suspension cultures. ce Heatmaps showing the breast epithelial subtype-specific gene expression15 across the samples. (Gene list in Supplementary Table 2).

Full size image

In addition, the expression of HS and BA cell genes in LASP cells reflects the presence of the basal-luminal (BL) subtype of LASP cells which expresses markers of both BA and HS cells. We and others previously identified a subset of LASP cells that exhibit a reduction in lineage fidelity and express genes typically associated with BA or HS, as well as genes that are not enriched in any subtype of breast epithelial cells15,16,17,18,19,20,21. The BL signature is also associated with basal-like breast cancer based on identified BL-enriched genes that are poorly expressed in breast epithelial cells (BL-unique)15. Indeed, we confirmed that the BL-unique genes are highly enriched in the isolated LASP cells (Supplementary Fig. 3a). We also examined differentially expressed genes in each individual epithelial lineage from organoids cultured in either Matrigel domes or as suspension cultures. This analysis showed that only four HS signature genes, five LASP-specific genes (all higher in domes), and 23 BA-specific genes (12 genes expressed higher in suspension and 11 expressed higher in domes) were differentially expressed under these two conditions (Supplementary Fig. 3b). Overall, RNA-seq data indicates that organoids cultured under both conditions can preserve the lineage fidelity of breast epithelial cells.

Hormone sensing cells can be isolated and propagated in the absence of other cell types

There is extensive crosstalk between the three subtypes of epithelial cells in vivo22. Since it would be useful to investigate and engineer HS cells independent of LASP and BA cells, we examined the properties of HS cells cultured alone. HS cells were isolated from seven different organoid lines by FACS using EpCAM and CD49f markers. To establish the HS cultures efficiently, we seeded EpCAMhigh/CD49flow HS cells in suspension at high density (see Methods) in organoid culture medium supplemented with 5% Matrigel. All HS lines were able to form dense sphere-like or acinar-like structures within two weeks in suspension culture (Fig. 4a). We then examined the differentiation of HS-only cultures after long term passaging. After more than two months of suspension culture, we dissociated the organoids and performed flow cytometry analysis using EpCAM and CD49f to assess the relative proportion of epithelial cell types. Almost all organoid lines contained a high proportion of HS cells (EpCAMhigh/CD49flow), >70% in 7/8 lines and over 90% in 5/8 lines (Fig. 4b–d). To validate the flow cytometry result, we isolated HS cells from ORG2, cultured them separately in suspension for two months, and then immune-stained for canonical lineage markers (FOXA1 for HS, CD133 for LASP, and α-SMA for BA). The HS-only cultures were largely FOXA1+ (93% FOXA1+ cells per total nuclei) and negative for CD133 and α-SMA (Fig. 4e). To directly assess the lineage fidelity of HS-only cultures, we performed bulk RNA-seq of HS cells from ORG6 cultured alone for 7 days and compared HS signature gene expression to HS cells isolated directly from mixed lineage organoid culture (data from Fig. 3). We found that HS cells cultured alone clustered with HS cells directly isolated from organoids and maintained high HS signature gene expression compared to LASP and BA cells (Supplementary Fig. 4a, b). These results indicate that HS cells can be cultured in suspension in the absence of other cell types without significantly compromising their lineage fidelity.

Fig. 4: Hormone sensing cells can be isolated and propagated in suspension cultures in the absence of other cell types.
figure 4

a Representative brightfield images of four suspension cultures derived from sorted single HS cells based on expression of EpCAM/CD49f and cultured more than 2 weeks. 4× magnification, scale bar 200 μm. b Representative flow cytometry plot of HS cultures isolated from ORG6. c Percentage of HS, LASP and BA cells based on EpCAM/CD49f expression of HS cultures isolated from ORG4 (n = 4) and ORG6 (n = 3) and cultured for over 2 months, mean ± SD. d Percentage of HS cells based on expression EpCAM/CD49f in HS cultures isolated from eight different organoid lines and cultured for more than two months. e Representative immunofluorescence confocal images of HS cultures isolated from ORG2. Fluorescently conjugated antibodies targeting FOXA1, CD133 and α-SMA were used to detect the three different epithelial lineages and DAPI for nuclei staining. 20× magnification, scale bar 100 μm.

Full size image

Organoids and HS cells cultured in suspension can activate ER signaling upon estrogen stimulation

To assess if the HS cells in organoid suspension cultures still express ER and activate ER downstream signals upon estrogen stimulation after long-term culture (>2 months), we first treated different organoid lines (passage 6–9) with physiological concentrations of estrogen (E2, 1 nM) and progesterone (P4, 50 nM). We used quantitative reverse transcription-PCR (qRT–PCR) to measure changes in the expression of ER signaling genes such as PR, TFF1 and GREB123,24,25 as well as WNT4, a key canonical paracrine signaling protein regulated by PR in HS cells26,27. E + P treatment for seven days induced TFF1, GREB1, PR and WNT4 in both organoids. TGFβ has been shown to suppress expression of ER and proliferation of HS cells28. While the organoid culture medium used in our experiments contains a TGFβ inhibitor (A83-01)15, we examined the effects of more effective TGFβ inhibition since it has been shown that supplementation with additional TGFβ inhibitors (SB431542 and RepSox) in cultures can increase ER expression and promote the growth of ER+ epithelial cells28,29. We found that of addition of RepSox and SB431542 increased the induction of ER downstream genes upon estrogen treatment (1.4-1.8-fold change in ORG2 and 1.4- to 3.7-fold in ORG5), without affecting ER expression in our organoid cultures. Moreover, induction of the PR-regulated gene WNT4 was increased with additional TGFβ inhibition (2.8 to 4-fold across all organoid lines) (Fig. 5a and Supplementary Fig. 5a). Overall, we confirmed that ER and ER responses can be preserved in long-term organoid suspension cultures.

Fig. 5: Organoids and HS cells cultured in suspension can activate ER signaling upon estrogen stimulation.
figure 5

a Expression of the indicated ER target genes in triplicate cultures from ORG2 and ORG5 suspension cultures after estrogen treatment for seven days, assessed by qRT-PCR (n = 3, mean ± SD). *p value < 0.05, **p value < 0.01, ***p value < 0.001, ****p value < 0.0001, paired t-Test, two-tailed. b Heatmap showing early and late estrogen response gene expression30 in HS cells isolated from three organoid lines in suspension cultures then treated with or without estrogen for seven days (duplicate) with p value < 0.05 as the cutoff. (Gene list in Supplementary Table 4). c Expression of the indicated ER target genes in triplicate HS cultures isolated from three organoid lines and treated with or without estrogen for seven days (n = 3, mean ± SD), assessed by qRT-PCR. *p value < 0.05, **p value < 0.01, paired t-Test, two-tailed. d Representative immunofluorescence confocal images of HS cultures from ORG1 and ORG2 treated with or without estrogen (E2) and stained for estrogen receptor (ER) and progesterone receptor (PR), scale bar 100 μm.

Full size image

To measure the ER responses in isolated HS cells, we isolated HS from three organoid lines by FACS and kept them in suspension cultures supplemented with estrogen for 7 days. RNA was extracted and sequenced. The PCA plots indicated the heterogeneity of different samples, even for those originally derived from the same organoids (Supplementary Fig. 5b). However, there were many significantly upregulated or downregulated genes following treatment with estrogen (Supplementary Fig. 5c). In addition, we detected upregulation of many estrogen response genes30 in estrogen-treated HS cells (Fig. 5b). To address whether long-term culture of HS cells can also preserve ER expression as well as ER responses, we performed qRT-PCR to measure changes in expression of ER signaling related genes of three HS lines after being cultured for more than two months with or without seven days estrogen treatment. qRT-PCR results show that all three HS lines can still respond to estrogen stimulation (Fig. 5c). Furthermore, immunofluorescence staining for ER and PR in five HS lines cultured for more than two months confirms ER positivity (Fig. 5d) within HS cells and high PR expression upon ER stimulation (Fig. 5d and Supplementary Fig. 5d).

To evaluate whether ER expression and ER responses are similiar in the two different conditions, we cultured isolated HS cells from two organoid lines (ORG6 and ORG11) in suspension cultures and Matrigel domes separately for 10 days, then supplemented with estrogen for 7 days. Target gene expression was evaluated by qRT-PCR. There were no consistent differences in induction of ER-target genes in Matrigel domes compared to suspension cultures across the two HS lines during this time frame (Supplementary Fig. 5e).

Overall, our findings indicate that organoids and HS-only suspension cultures maintain ER expression and ER signaling and can be used as tools to study ER-related regulation in normal breast epithelial cells.

Discussion

Organoids have been used extensively as in vitro models to investigate the development and physiology of normal organs and diseases including cancer. However, improvements to current breast organoid culture methodologies are needed to improve their utility. Here, we describe a modified organoid culture system for more effective expansion of normal breast organoids that maintain bilayered organoid morphology, lineage fidelity, and hormone receptor expression and responsiveness. As a result, our method represents a powerful tool to study estrogen and estrogen receptor regulation in normal tissues and ER positive breast cancer.

The conventional organoid culture system embedding organoids inside Matrigel domes was designed to recapitulate the in vivo extracellular matrix environment. However, passage of conventional dome cultures requires steps to break down Matrigel mechanically or enzymatically to separate organoids from mixtures. This physical stress could negatively affect organoid growth rate because organoids need more time to recover and reorganize following the harsher dissociation steps10,12,31,32,33. Moreover, the solid Matrigel dome culture system for normal breast organoids poses many challenges, such as requiring tedious steps for organoid propagation and failure to maintain bilayered organoid structures over time12,14,34. Our method using organoid culture medium supplemented with a low percentage of Matrigel (5%) simplifies the culture procedures for easier handling while still providing the sufficient extracellular matrix for organoid formation. Although the ratio of three epithelial lineages (HS, LASP and BA) was not significantly distinguished in dome or suspension cultures, organoids formed in suspension were larger and formed more uniform sphere structures than those in Matrigel domes. The structure size correlated with the proportion of proliferating cells in suspension cultures (Fig. 2c, e, Supplementary Fig. 1c–e, Supplementary Fig. 2b, c). It is also possible that suspension conditions allow cells to more efficiently migrate and aggregate compared to dome embedding. The maintenance of a bilayered morphology in suspension culture, with BA cells surrounding the luminal cells, could also contribute to the more uniform sphere structures (Supplementary Fig. 1g).

Bulk RNA seq analysis of the three breast epithelial cell types indicated that these three lineages maintain their cell identities in both types of organoid cultures. We detected minimal differences in cell identity signature genes in organoids cultured in domes or suspension. HS cells isolated from organoids in both culture conditions displayed higher lineage fidelity than LASP and BA cells (Fig. 3a). LASP cell populations expressed a few HS and BA genes; however, this is predicted based on the known presence of cell populations that display reduced lineage fidelity in human breasts. These cells, referred to as basal-luminal or BL cells, are enriched for genes specifically associated with BA or HS cells as well as genes that are expressed at very low levels or not at all in breast epithelial cells (BL-unique genes)15,20,21. The heatmap of BL-unique signature genes in Supplementary Fig. 3a indicates that the organoid cultures maintain BL cells. Thus, some of the BA (KRT17, PTN, SPP1) and HS (FAM102A, HIGD1A, WFDC2) genes that are expressed in LASP cells are likely due to the presence of a BL cell population in this cluster. Other BA genes expressed in LASP cells could be derived from BA cells that have undergone partial differentiation, sufficient for these cells to be sorted with LASP cells (e.g. decreased CD49f and increased EpCAM). Likewise, BA cells expressing LASP markers could have undergone a partial differentiation to LASP cells, without affecting CD49f/EpCAM sorting. BA cells have been reported to express LASP markers after being dissociated from luminal cells which are critical to maintain BA cell identity6,35,36.

Importantly, we were able to maintain purified HS cell organoids in suspension cultures while still maintaining extremely high purity after short-term (Supplementary Fig. 4a) or long-term culture (Fig. 4b–d). For a few HS organoid cultures, we did detect small percentages of LASP and BA cells. This could result from insufficient gating of HS cells during FACS using CD49f and EpCAM. Use of an additional sorting step or inclusion of more surface markers such CD166 for HS cells17,35, CD133 for LASP cells15,37 and CD10 for BA cells38 could also increase the purity of HS cells. Overall, we confirmed that HS cells can be isolated and cultured alone without losing cell identity (Supplementary Fig. 4a, b).

We found that the purified HS cells maintain expression of ER and respond to estrogen stimulation after long-term culture (Fig. 5c). We did not observe any consistent differences in ER-target gene expression comparing HS cells cultured in Matrigel domes to suspension cultures, suggesting that ER expression and ER responses are not influenced by the Matrigel conditions during the time frame we examined, and vary predominantly by donor (Supplementary Fig. 5e). Progesterone receptor induction of its target gene WNT4 was only detected when organoids were cultured with additional TGFβ inhibitors (Supplementary Fig. 5a), consistent with previous studies using other medium conditions28,29.

One issue that all breast organoid investigations have reported is the heterogeneity of organoids from different donors. As observed previously12,14, we detected widely varying proportions of the three main cell lineages in organoid cultures from different donors. There are several factors that may account for this variation, such as age, menopause status, BMI, or genetic background (e.g., BRCA mutations). This heterogeneity makes it very difficult to identify phenotypic differences in organoids that can be attributed to the factors mentioned above. However, the proportions of each lineage from a single organoid line are maintained for several passages12,14, thus making it feasible to use genetic or pharmacological perturbations within the same organoid lines to address mechanistic questions.

In conclusion, our results demonstrate that organoid suspension cultures represent a valuable in vitro platform to study ER and estrogen regulation in HS cells from normal breast, enabling studies of ER-positive breast cancer initiation that were not previously feasible.

Methods

Generation of organoids from breast tissues

Breast tissues were obtained from reduction mammoplasty or prophylactic mastectomy samples at Brigham & Women’s Hospital. Harvard Medical School Institutional Review Board reviewed this study and deemed it not human subject research. Donors gave informed consent to have their tissue used for research purposes. Tissues were processed as previously described14. Briefly, tissues were processed on the day of surgery by mincing into small chunks. Minced tissue was placed into a conical tube containing triple+ Adv medium (Advanced DMEM/F12 supplemented with 1× Glutamax, 10 mM HEPES, and Pen-Strep) and 1 mg/ml collagenase (Sigma, C9407) for tissue dissociation. Some of the viable minced tissue was also frozen (in FBS with 10% DMSO) for future use. Tubes were placed in the orbital shaker at 37 °C for 2 h. After collagenase dissociation, triple+ Adv medium with 2% FBS was added before centrifugation. The dissociated tissue pellets were resuspended in 10 ml triple+ Adv medium and underwent further mechanical shearing into small clusters of 20–60 cells by sequential pipetting with 10 and 5 ml serological pipettes. Supplementary Table 1 provides information on the donor tissues employed in this study.

Organoid cultures

Organoids were cultured as previously described12,14. For Matrigel dome cultures, primary breast organoids were resuspended in Matrigel growth factor reduced (GFR) basement membrane matrix (Corning, cat. No. 354230) and dropped in the center of a well in a 24-well culture plate (Corning, cat. No. 3524) and placed at 37 °C incubator for 10–20 min to form the solid domes before adding organoid culture medium (Supplementary Note 1). Medium was changed twice per week, and organoids were passaged using TrypLE™ Express Enzyme (1X), no phenol red (Gibco, cat. No. 12604013) to dissociate into small clusters when organoids reached 80% confluency in the domes (about every 2–4 weeks). For suspension organoid cultures, primary breast organoids were resuspended in organoid culture medium containing 5% Matrigel and cultured in Costar® 24-well ultra-low attachment plates (Corning, cat. No. 3473). Suspension cultures were supplemented with an equal amount of fresh organoid culture medium containing 5% Matrigel every 3–4 days and transfered to larger culture wells to maintain 40–70% confluency. When most organoids reached 100–200 μm size, we passaged them by using TrypLE™ Express Enzyme (1X), no phenol red (Gibco, cat. No. 12604013) to dissociate into small clusters (about every 2–4 weeks). Dissociated small organoid clusters were collected into 15 ml conical tubes and centrifuged at 500rcf for 4 min. Supernatants were removed and the organoid pellets were resuspended with organoid culture medium containing 5% Matrigel. For seeding of HS-only cultures, we seeded EpCAMhigh/CD49flow HS cells in suspension at a density of 40,000–50,000 cells in 500 μl organoid culture medium supplemented with 5% Matrigel.

Hormone stimulation

Cultures were treated for seven days with 1 nM beta-estradiol in organoid culture medium added on days 1, 4 and 7, and 50 nM progesterone added at day seven for 7 h before RNA extraction.

Flow cytometry and Click-iT EdU assay

Organoid cultures were treated with 5-ethynyl-2’-deoxyuridine (EdU) at 10 µM for 48 h, then dissociated to single cells by TrypLE express enzyme. Cells were fixed and labeled using the Click-iT™ Plus EdU Alexa Fluor™ 488 Flow Cytometry Assay Kit (Invitrogen, Cat. No. C10632) following the manufacturer’s protocol combined with the breast epithelial lineage markers Alexa Fluor 647-conjugated anti-EpCAM (BioLegend, Cat. No. 324212) (1:100) and phycoerythrin-conjugated anti-CD49f (BioLegend, Cat. No. 313612) (1:100). Flow cytometry data were analyzed with FlowJo software.

Fluorescence-activated cell sorting (FACS) isolation of mammary epithelial lineage cells

Organoid cultures were dissociated into single cells as described above and labeled with Alexa Fluor 647-conjugated anti-EpCAM (1:100) and phycoerythrin-conjugated anti-CD49f (1:100) in staining buffer (dPBS contained 2% FBS and 20 mM HEPES) for 1 h at room temperature. EpCAMhigh CD49flow HS cells, EpCAMhigh CD49fhigh LASP cells, and EpCAMlow CD49fhigh BA cells were sorted on a SONY SH800S Cell Sorter. Sorted cells were cultured in organoid culture medium with 5% Matrigel or immediately used for RNA extraction. Flow cytometry data were analyzed with FlowJo software.

Immunofluorescence (IF)

Immunofluorescence performed as described previously39 with minor modifications depending on the specific antibodies. Cultured organoids or cells were transferred onto Falcon® 8-well Culture Slides (Corning, cat. No. 354118) and fixed in 4% formaldehyde for 15 min. Samples were permeabilized in 0.5% Triton X in dPBS for 15 min and then blocked for 1 h in 1% BSA in IF solution (dPBS with 0.2% Triton X and 0.05% Tween 20). For unconjugated primary antibodies, samples were incubated at the appropriate concentration (1:100 for CD133, 1:150 for α-SMA) of primary antibody overnight at 4 °C and incubated in diluted (1:200–1:400) secondary antibody conjugated with fluorophores for 1 h at room temperature. For direct conjugated primary antibodies, samples were incubated in the appropriate concentration (1:100 for ERα, 1:150 for PR, 1:200 for FOXA1) of primary antibody conjugated with fluorophores overnight at 4 °C. Nuclei were stained with DAPI. After staining, slides were mounted in ProLong™ Gold Antifade Mountant (Invitrogen, Cat. No. P36930) before detection. Stained samples were imaged on the Nikon A1R point scanning confocal microscope or Nikon AX-R point scanning confocal microscope. Images were processed and analyzed using NIS-Elements Viewer and ImageJ software.

RNA isolation

Total RNA was extracted using TRIzol/Chloroform method according to the manufacturer’s instructions with nuclease-free reagents. For organoids in 24-well plates, 1 ml TRIzol per well was used for the RNA extraction and a ratio of 200 µl chloroform to 1 ml of TRIzol reagent for separation. RNA was precipitated from the aqueous phase with isopropyl alcohol at a ratio 0.5 ml to 1 ml of TRIzol and 1 µl GlycoBlue™ Coprecipitant (Invitrogen, Cat. No. AM9516). The RNA pellet was washed with 75% ethanol once, air-dried and resuspended in 10 µl nuclease-free water (Invitrogen, Cat. No. AM9932). RNA concentration was measured by A260/A230 and A260/A280 ratios on a Nanodrop One. RNA samples were used for reverse transcription and quantitative real-time PCR or RNA sequencing.

Reverse transcription and quantitative real-time PCR (qRT-PCR)

1 μg of total RNA per sample was used for reverse transcription. After DNase I digestion, RNA samples were reverse transcribed into cDNA using TaqMan Reverse Transcription Reagent kit (Invitrogen, Cat. No. N8080234) according to manufacturer’s instructions. cDNA samples mixed with primer sets and Power SYBR Green PCR Master Mix (Applied Biosystems™, Cat. No. 4367659) were used for qRT-PCR on an Applied Biosystems QuantStudio 7 Pro machine. Human RPS28 and RPL13A were used as endogenous controls to normalize each sample. Reagents and primer sequences used in this study are provided in Supplementary Note 2.

RNA sequencing (RNA-seq) and data analysis

RNA samples were sent to Novogen for library preparation and mRNA sequencing using Illumina NovaSeq 6000 and X-Plus Sequencing Platform (paired-end 150 bp). Data were analyzed using Partek Flow software. Briefly, reads were mapped to hg38 using STAR2.7.8a then quantified to annotation model by Partek E/M (GENCODE genes version 38). Differential gene expression was performed with DESeq2, and FDR < 0.1 or p-value < 0.05 was used as a threshold for statistical significance. Heatmaps were generated by applying signature gene lists15,30.

Quantification and statistical analysis

Statistical tests were performed and analyzed using Microsoft Excel and GraphPad Prism 10 with p value analysis setting (paired t-Test, two-tailed). Significance was defined as p < 0.05.

Related Articles

The Breast Cancer Classifier refines molecular breast cancer classification to delineate the HER2-low subtype

Current breast cancer classification methods, particularly immunohistochemistry and PAM50, face challenges in accurately characterizing the HER2-low subtype, a therapeutically relevant entity with distinct biological features. This notable gap can lead to misclassification, resulting in inappropriate treatment decisions and suboptimal patient outcomes. Leveraging RNA-seq and machine-learning algorithms, we developed the Breast Cancer Classifier (BCC), a unique transcriptomic classifier for more precise breast cancer subtyping, specifically by delineating and incorporating HER2-low as a distinct subtype. BCC also redefined the PAM50 Normal subtype into other subtypes, disputing its classification as a unique molecular group. Our statistical analysis not only confirmed the reproducibility and accuracy of BCC, but also revealed similarities in prognostic characteristics between the HER2-low and Basal subtypes. Addressing this gap in breast cancer classification is clinically significant because it not only improves treatment stratification, but also uncovers novel molecular and immunohistochemical features associated with the HER2-low and HER2-high subtypes, thereby advancing our understanding of breast cancer heterogeneity and providing guidance in precision oncology.

Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies

Trastuzumab deruxtecan (T-DXd) is approved for HER2-low (HER2 immunohistochemistry (IHC)1+ or 2+ with non-amplified in situ hybridization (ISH)), but not HER2-0 (IHC 0) metastatic breast cancer. The impact of repeat biopsies (Bxs) in identifying new potential candidates with triple negative breast cancer (TNBC) for T-DXd treatment remains unknown. 512 consecutive patients with TNBC at diagnosis were included in the study cohort. Bxs were categorized as core, surgical, or metastatic based on the timing and method of biopsy (Bx) acquisition, and the total number of Bxs was determined for each patient. Additionally, matched biopsies were identified, and the rate of discordance in HER2 status was calculated. The proportion of patients with at least one HER2-low result increased as the number of successive Bxs increased [59%, 73%, 83%, 83%, and 100% when 1 (196 patients), 2 (231 patients), 3 (48 patients), 4 (29 patients), and ≥ 5 (8 patients) Bxs were obtained, respectively]. Among patients without a prior HER2-low result, approximately one-third demonstrated HER2-low status with each additional successive Bx. HER2 status exhibited variability between matched Bxs, with observed discordance rates of 26%, 44%, and 33% between matched core-surgical, early-metastatic, and two metastatic matched Bxs, respectively. Our findings indicate that HER2 status can vary between different Bxs taken during the disease course of patients with TNBC with the highest discordance rate observed between the primary and metastatic Bxs. For patients with metastastic HER2-0 TNBC, repeat Bxs can increase the chance of obtaining a HER2-low result, thereby offering patients a promising therapeutic option.

Type 2 immunity in allergic diseases

Significant advancements have been made in understanding the cellular and molecular mechanisms of type 2 immunity in allergic diseases such as asthma, allergic rhinitis, chronic rhinosinusitis, eosinophilic esophagitis (EoE), food and drug allergies, and atopic dermatitis (AD). Type 2 immunity has evolved to protect against parasitic diseases and toxins, plays a role in the expulsion of parasites and larvae from inner tissues to the lumen and outside the body, maintains microbe-rich skin and mucosal epithelial barriers and counterbalances the type 1 immune response and its destructive effects. During the development of a type 2 immune response, an innate immune response initiates starting from epithelial cells and innate lymphoid cells (ILCs), including dendritic cells and macrophages, and translates to adaptive T and B-cell immunity, particularly IgE antibody production. Eosinophils, mast cells and basophils have effects on effector functions. Cytokines from ILC2s and CD4+ helper type 2 (Th2) cells, CD8 + T cells, and NK-T cells, along with myeloid cells, including IL-4, IL-5, IL-9, and IL-13, initiate and sustain allergic inflammation via T cell cells, eosinophils, and ILC2s; promote IgE class switching; and open the epithelial barrier. Epithelial cell activation, alarmin release and barrier dysfunction are key in the development of not only allergic diseases but also many other systemic diseases. Recent biologics targeting the pathways and effector functions of IL4/IL13, IL-5, and IgE have shown promising results for almost all ages, although some patients with severe allergic diseases do not respond to these therapies, highlighting the unmet need for a more detailed and personalized approach.

Targeting of TAMs: can we be more clever than cancer cells?

With increasing incidence and geography, cancer is one of the leading causes of death, reduced quality of life and disability worldwide. Principal progress in the development of new anticancer therapies, in improving the efficiency of immunotherapeutic tools, and in the personification of conventional therapies needs to consider cancer-specific and patient-specific programming of innate immunity. Intratumoral TAMs and their precursors, resident macrophages and monocytes, are principal regulators of tumor progression and therapy resistance. Our review summarizes the accumulated evidence for the subpopulations of TAMs and their increasing number of biomarkers, indicating their predictive value for the clinical parameters of carcinogenesis and therapy resistance, with a focus on solid cancers of non-infectious etiology. We present the state-of-the-art knowledge about the tumor-supporting functions of TAMs at all stages of tumor progression and highlight biomarkers, recently identified by single-cell and spatial analytical methods, that discriminate between tumor-promoting and tumor-inhibiting TAMs, where both subtypes express a combination of prototype M1 and M2 genes. Our review focuses on novel mechanisms involved in the crosstalk among epigenetic, signaling, transcriptional and metabolic pathways in TAMs. Particular attention has been given to the recently identified link between cancer cell metabolism and the epigenetic programming of TAMs by histone lactylation, which can be responsible for the unlimited protumoral programming of TAMs. Finally, we explain how TAMs interfere with currently used anticancer therapeutics and summarize the most advanced data from clinical trials, which we divide into four categories: inhibition of TAM survival and differentiation, inhibition of monocyte/TAM recruitment into tumors, functional reprogramming of TAMs, and genetic enhancement of macrophages.

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

Additional therapies are needed to improve outcomes in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative breast cancer. Research on the potential role of immunotherapy, particularly programmed cell death protein 1/programmed cell death ligand 1 inhibitors, is rapidly expanding in both the early and metastatic settings with some preliminary evidence suggesting benefit when used as part of combination therapy. Several ongoing phase 3 studies should help define their future role in treating these patients.

Responses

Your email address will not be published. Required fields are marked *